Miyoshi Y, Nakamura H, Sasaki S, Tagami T, Misaki T, Konishi J, Nakao K
Department of Internal Medicine, Kyoto University School of Medicine, Japan.
Mol Cell Endocrinol. 1995 Oct 30;114(1-2):9-17. doi: 10.1016/0303-7207(95)03636-l.
We identified unusual mutations in the T3 receptor (TR) beta gene in a 6-year-old Japanese girl with generalized resistance to thyroid hormone. Two consecutive base substitutions, T to A and C to A at nucleotide positions 1637 and 1638, respectively, changed the 451st codon coding for Phe(TTC) to stop codon (TAA), resulting in an 11-amino acid carboxyl(C)-terminus truncation. The patient was a heterozygote. Western blotting using an anti-TR antibody demonstrated the truncated receptor protein. The patient showed severe mental retardation (IQ41), disturbance in speech development, and attention deficit hyperactivity disorder. Thyroid functional status by clinical evaluation was considered within the normal range in spite of high serum thyroid hormone levels (T4 725.9 nmol/l, T3 12.7 nmol/l, FT4 166.0 pmol/l). TSH increased from 0.6 to 24 mU/L after TRH (150 micrograms) injection. TSH secretion as well as 123I-uptake was suppressed only partially by T3 (75 micrograms/day for a week). Close examination of thyroid functions and TR beta gene analysis were not possible in the family, except for paternal grandmother and one of her two sisters who showed no abnormality. The patient's truncated TR beta showed very low T3 binding activity (Ka = 0.1 x 10-10 M), transcriptional activity, and a very strong dominant negative effect. When co-expressed with wild-type TR beta at the molar ratio 1:1 in CV-1 cells, the mutant receptor inhibited the wild-type TR beta transcriptional activity by 74% at 10 nM T3. Even 1 microM T3 could not normalize these impaired functions.
我们在一名对甲状腺激素具有全身性抵抗的6岁日本女孩中,鉴定出了甲状腺激素受体(TR)β基因的异常突变。在核苷酸位置1637和1638处,分别发生了两个连续的碱基替换,即从T替换为A以及从C替换为A,这使得编码苯丙氨酸(TTC)的第451位密码子变为终止密码子(TAA),导致羧基(C)末端截短了11个氨基酸。该患者为杂合子。使用抗TR抗体进行的蛋白质印迹法证实了截短的受体蛋白的存在。该患者表现出严重的智力发育迟缓(智商41)、言语发育障碍以及注意力缺陷多动障碍。尽管血清甲状腺激素水平较高(T4 725.9 nmol/l,T3 12.7 nmol/l,FT4 166.0 pmol/l),但通过临床评估甲状腺功能状态仍被认为在正常范围内。注射促甲状腺激素释放激素(TRH,150微克)后,促甲状腺激素(TSH)从0.6升高至24 mU/L。仅部分抑制了TSH分泌以及123I摄取(每天75微克T3,持续一周)。除了患者的祖母和她的两个姐妹之一未表现出异常外,无法对该家族进行甲状腺功能的详细检查以及TRβ基因分析。患者截短的TRβ表现出非常低的T3结合活性(Ka = 0.1×10-10 M)、转录活性以及非常强的显性负效应。当在CV-1细胞中以1:1的摩尔比与野生型TRβ共表达时,突变受体在10 nM T3时抑制野生型TRβ转录活性达74%。即使是1 microM T3也无法使这些受损功能恢复正常。